Abstract CT064: Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Bilal A. Siddiqui(The University of Texas MD Anderson Cancer Center), Elizabeth Miller(Unknown), Sabina Sandigursky(Regeneron (United States)), Israel Lowy(Bristol-Myers Squibb (Germany)), Matthew Ingham(Columbia University), Kevin Zarrabi(Stony Brook University), Pradeep Thanigaimani(Regeneron (United States)), Edward P. Gelmann(University of Arizona), Joseph W. Kim(National Cancer Institute), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Benedito A. Carneiro(Brown University), Mark N. Stein(Cornell University), Shilpa Govindraj(Regeneron (United States)), David R. Wise, Dimitris Skokos(Regeneron (United States)), Fang Fang(Jinshan Hospital of Fudan University), Xīn Gào(Qingdao University), Jingsong Zhang(Moffitt Cancer Center), Przemyslaw Twardowski(Saint John's Health Center), Jennifer S. Sims(Columbia University Irving Medical Center), Divya Rana(St. James's Hospital), Che‐Kai Tsao(Mount Sinai Hospital), Frank Seebach(Regeneron (United States))
Cited by 3
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k